Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immatics N.V.
While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
The promise of Immatics’ T-cell redirecting cancer immunotherapy technology for solid tumors has been spotlighted in early clinical studies in heavily pre-treated and refractory cancer patients.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Immatics Biotechnologies GmbH